Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case‐Control Study
暂无分享,去创建一个
Mario Cannataro | Giuseppe Agapito | Mariamena Arbitrio | Francesca Scionti | Pierosandro Tagliaferri | Pierfrancesco Tassone | Emanuela Altomare | Daniele Caracciolo | M. Cannataro | P. Tassone | P. Tagliaferri | Giuseppe Agapito | G. Arpino | M. Arbitrio | D. Caracciolo | D. Santini | F. Scionti | Maria Teresa Di Martino | Teresa Galeano | Nicoletta Staropoli | Eleonora Iuliano | Francesco Grillone | Fernanda Fabiani | Grazia Arpino | Daniele Santini | E. Altomare | Eleonora Iuliano | F. Grillone | T. Galeano | N. Staropoli | F. Fabiani | M. T. Di Martino
[1] Jeffrey Bell,et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. , 2006, Gynecologic oncology.
[2] F. Balloux,et al. Discriminant analysis of principal components: a new method for the analysis of genetically structured populations , 2010, BMC Genetics.
[3] M. Smid,et al. Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics , 2015, The Pharmacogenomics Journal.
[4] Ronald W. Davis,et al. Multiplexed genotyping with sequence-tagged molecular inversion probes , 2003, Nature Biotechnology.
[5] Yusuke Nakamura,et al. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel‐induced leukopenia , 2008, Cancer science.
[6] L. Carey,et al. CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] Douglas G. Altman,et al. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration , 2012, PLoS medicine.
[8] Mario Cannataro,et al. DMET-Analyzer: automatic analysis of Affymetrix DMET Data , 2012, BMC Bioinformatics.
[9] Mario Cannataro,et al. Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis , 2015, Cancer Chemotherapy and Pharmacology.
[10] Mario Cannataro,et al. Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: A DMET microarray profiling study , 2011, Cancer biology & therapy.
[11] Bradley L Urquhart,et al. Nuclear Receptors and the Regulation of Drug‐Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs , 2007, Journal of clinical pharmacology.
[12] W. Engel-Riedel,et al. A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer , 2018, Journal of Immunotherapy for Cancer.
[13] E. Tan,et al. Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRα and HNF4α) on docetaxel disposition in Chinese nasopharyngeal cancer patients , 2013, European Journal of Clinical Pharmacology.
[14] P. Mackenzie,et al. Suppression of Cytochrome P450 3A4 Function by UDP-Glucuronosyltransferase 2B7 through a Protein-Protein Interaction: Cooperative Roles of the Cytosolic Carboxyl-Terminal Domain and the Luminal Anchoring Region , 2015, Molecular Pharmacology.
[15] U. Langsenlehner,et al. Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer , 2011, Breast Cancer Research.
[16] A. Starlard-Davenport,et al. Identification of UDP-glucuronosyltransferase 1A10 in non-malignant and malignant human breast tissues , 2008, Steroids.
[17] Giuseppe Agapito,et al. Genetic variants associated with Fabry disease progression despite enzyme replacement therapy , 2017, Oncotarget.
[18] Giuseppe Agapito,et al. Genetic variants associated with gastrointestinal symptoms in Fabry disease , 2016, Oncotarget.
[19] Taosheng Chen,et al. Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery. , 2017, Current drug metabolism.
[20] Mario Cannataro,et al. DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine , 2016, Oncotarget.
[21] K. Haruma,et al. Single nucleotide polymorphism markers for low‐dose aspirin‐associated peptic ulcer and ulcer bleeding , 2014, Journal of gastroenterology and hepatology.
[22] Mario Cannataro,et al. A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling , 2011, British journal of haematology.
[23] K. Kuroi,et al. Neurotoxicity of taxanes: Symptoms and quality of life assessment , 2004, Breast cancer.
[24] W. Vach,et al. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer , 2011, European Journal of Clinical Pharmacology.
[25] G. Toffoli,et al. Nuclear receptors and drug metabolism for the personalization of cancer therapy , 2016, Expert opinion on drug metabolism & toxicology.
[26] Ann Daly,et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.
[27] M. Koltzenburg,et al. Peripheral nerve damage associated with administration of taxanes in patients with cancer. , 2008, Critical reviews in oncology/hematology.
[28] P. Mackenzie,et al. Glucosidation of hyodeoxycholic acid by UDP-glucuronosyltransferase 2B7. , 2003, Biochemical pharmacology.
[29] Howard L McLeod,et al. Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.
[30] C. Caldas,et al. Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel , 2014, Clinical Cancer Research.
[31] W. Sauerbrei,et al. Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.
[32] I. Pogribny,et al. The role of UDP-glucuronosyltransferases and drug transporters in breast cancer drug resistance. , 2010, Experimental oncology.
[33] M. Negishi,et al. Sulfotransferase genes: Regulation by nuclear receptors in response to xeno/endo-biotics , 2013, Drug metabolism reviews.
[34] R. Milne,et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity , 2011, The Pharmacogenomics Journal.
[35] E. Wiemer,et al. CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity , 2013, Clinical Cancer Research.
[36] U. Argikar,et al. UDP-Glucuronosyltransferases , 2019, Handbook of Drug Metabolism.
[37] P. Hardenbol,et al. Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System. , 2007, Pharmacogenomics.
[38] S. Aliño,et al. SNPs and taxane toxicity in breast cancer patients. , 2014, Pharmacogenomics.
[39] A. Tsalenko,et al. SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance , 2010, The Pharmacogenomics Journal.
[40] David J. Hand,et al. A Simple Generalisation of the Area Under the ROC Curve for Multiple Class Classification Problems , 2001, Machine Learning.
[41] A. H. Tolson,et al. Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. , 2010, Advanced drug delivery reviews.